Scholarlink

Background <p>The objectives of this study are to compare clinicopathological features and outcomes of extraskeletal osteosarcoma (EOS) and conventional osteosarcoma (COS) and identify independent prognostic factors for disease-free survival (DFS) and overall survival (OS).</p> Methods <p>This study included 72 patients (Group EOS, <i>n</i> = 12; Group COS, <i>n</i> = 60) with a definitive diagnosis. Clinicopathological variables, SATB2 expression, and Ki-67 proliferation index were compared between groups. Outcomes were assessed using the Kaplan–Meier method and the log-rank test, and independent prognostic factors were identified by Cox regression analysis.</p> Results <p>Group EOS had significantly higher median age (53.5 vs. 33.4 years, <i>p</i> &lt; 0.001) and Ki-67 proliferation index than Group COS. Primary tumor location differed significantly (<i>p</i> &lt; 0.001), with EOS cases affecting internal organs (kidneys, lungs) and COS cases mainly in long bones around the knee. Metastases were more common in Group EOS (83.3% vs. 13.6%, <i>p</i> &lt; 0.001). Median OS and DFS for Group EOS were 19.3 months (vs. 71.6 months for COS, <i>p</i> = 0.007) and 2.2 months (vs. 21.6 months for COS, <i>p</i> &lt; 0.001), respectively. Multivariate analysis identified age (OS: HR per year 1.04, 95% CI: 1.02–1.06, <i>p</i> &lt; 0.001; DFS: HR 1.03, 95% CI: 1.02–1.05, <i>p</i> &lt; 0.001) and Ki-67 proliferation index (OS: HR per %-point 1.02, 95% CI: 1.00–1.04, <i>p</i> = 0.038; DFS: HR 1.02, 95% CI: 1.01–1.04, <i>p</i> = 0.006) as independent prognostic factors.</p> Conclusions <p>Survival outcomes for patients with EOS were significantly worse than for those with COS. High Ki-67 proliferation index and advanced age were associated with a more aggressive clinical course of EOS. Therefore, more intensive follow-up and treatment are prudent for elderly EOS patients with a high Ki-67 proliferation index.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High Ki-67 as an independent prognostic factor in extraskeletal osteosarcoma: a comparative cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月4日

查看全文
  • Hülya Odabaşı Bükün,
  • Türkkan Evrensel,
  • Erdem Çubukçu,
  • Adem Deligönül,
  • Ahmet Bilgehan Şahin,
  • Ender Eren Özçelik,
  • Ömer Can Kaya,
  • Ülviye Yalçınkaya,
  • Seyit Ali Volkan Polatkan

摘要

Background

The objectives of this study are to compare clinicopathological features and outcomes of extraskeletal osteosarcoma (EOS) and conventional osteosarcoma (COS) and identify independent prognostic factors for disease-free survival (DFS) and overall survival (OS).

Methods

This study included 72 patients (Group EOS, n = 12; Group COS, n = 60) with a definitive diagnosis. Clinicopathological variables, SATB2 expression, and Ki-67 proliferation index were compared between groups. Outcomes were assessed using the Kaplan–Meier method and the log-rank test, and independent prognostic factors were identified by Cox regression analysis.

Results

Group EOS had significantly higher median age (53.5 vs. 33.4 years, p < 0.001) and Ki-67 proliferation index than Group COS. Primary tumor location differed significantly (p < 0.001), with EOS cases affecting internal organs (kidneys, lungs) and COS cases mainly in long bones around the knee. Metastases were more common in Group EOS (83.3% vs. 13.6%, p < 0.001). Median OS and DFS for Group EOS were 19.3 months (vs. 71.6 months for COS, p = 0.007) and 2.2 months (vs. 21.6 months for COS, p < 0.001), respectively. Multivariate analysis identified age (OS: HR per year 1.04, 95% CI: 1.02–1.06, p < 0.001; DFS: HR 1.03, 95% CI: 1.02–1.05, p < 0.001) and Ki-67 proliferation index (OS: HR per %-point 1.02, 95% CI: 1.00–1.04, p = 0.038; DFS: HR 1.02, 95% CI: 1.01–1.04, p = 0.006) as independent prognostic factors.

Conclusions

Survival outcomes for patients with EOS were significantly worse than for those with COS. High Ki-67 proliferation index and advanced age were associated with a more aggressive clinical course of EOS. Therefore, more intensive follow-up and treatment are prudent for elderly EOS patients with a high Ki-67 proliferation index.